Cutz (T3 Liothyronine Sodium + SR-9011 + Yohimbine) – Product Information
Cutz is a research product that combines T3 Liothyronine Sodium, SR-9011, and Yohimbine to investigate their potential synergistic effects. T3 Liothyronine Sodium is a compound known for its impact on thyroid activity and metabolism. SR-9011, a REV-ERB agonist, is believed to influence circadian rhythm and metabolic processes. Yohimbine, an alpha-2 adrenergic receptor antagonist, may have effects on various physiological processes such as blood flow and fat metabolism.
The combination of T3 Liothyronine Sodium, SR-9011, and Yohimbine in Cutz offers researchers the opportunity to explore their collective impact on metabolism, energy regulation, and potential fat loss. However, it is crucial to reiterate that Cutz is strictly intended for research purposes.
- Cutz consists of T3 Liothyronine, SR-9011, and Yohimbine.
- Cutz Transdermal is offered as 60ml/17.6mg per ml/1g.
- Cutz Injectable is offered as 10ml/100mg per ml/1g.
T3 Liothyronine Sodium (or more specifically, thyroid hormones in general) are investigated for their interactions with fat mass since, in survey research, thyroid activity may be related to fat mass and BMI. A recent study on the effects of T3 on rats found that the increased expression of thyroid hormone receptor beta (T3’s receptor) that is increased during caloric restriction is not abolished by T3 supplementation and that T3 supplementation leads to increased leptin gene expression.
Overall, the data seem to suggest that T3 does not necessarily spike metabolic rate but that it minimizes a decline seen in metabolic rate due to prolonged caloric restriction. This warrants a massive potential of T3 as a possible weight loss aid.
|T3 Liothyronine Sodium|
|Molar Mass||650,9735 g/mol|
SR-9011 is a research compound that falls under the category of REV-ERB agonists. It is a synthetic compound that has been developed for research purposes to explore its potential effects on various physiological processes. A recent study on diet-induced obese mice treated with SR9009 and SR9011 (i.e., two times a day for 30 days) has been reported to display decreased fat mass and markedly improved dyslipidemia and hyperglycemia. The activation of REV-ERB leads to the enhancement of circadian rhythm observed in mice. This affects behavior, sleep cycle, and some functions related to an increment in energy production.
|Molar Mass||479.04 g·mol−1|
Yohimbine is a compound derived from the bark of the yohimbe tree (Pausinystalia yohimbe) and is of interest in research fields. It is classified as an alpha-2 adrenergic receptor antagonist, meaning it blocks the action of these receptors. Yohimbine has been studied for its potential effects on various physiological processes, such as its impact on blood flow, sexual function, and potential role in fat metabolism.
|Molar Mass||354.450 g·mol−1|
|IUPAC Name||17α-hydroxy-yohimban-16α- carboxylic acid methyl ester|